Edition:
United States

Proteon Therapeutics Inc (PRTO.OQ)

PRTO.OQ on NASDAQ Stock Exchange Global Market

2.50USD
3:04pm EDT
Change (% chg)

$0.10 (+4.17%)
Prev Close
$2.40
Open
$2.35
Day's High
$2.50
Day's Low
$2.35
Volume
529
Avg. Vol
5,378
52-wk High
$2.90
52-wk Low
$1.27

Chart for

About

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $47.72
Shares Outstanding(Mil.): 17.67
Dividend: --
Yield (%): --

Financials

  PRTO.OQ Industry Sector
P/E (TTM): -- 214.90 33.15
EPS (TTM): -2.07 -- --
ROI: -94.57 -3.85 13.23
ROE: -177.19 -5.38 15.27

BRIEF-Proteon Therapeutics Announces Qtrly Loss Per Share $0.34

* PROTEON THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Proteon Therapeutics And Lonza Extend Manufacturing Agreement For Commercial Supply

* PROTEON THERAPEUTICS AND LONZA EXTEND MANUFACTURING AGREEMENT FOR COMMERCIAL SUPPLY

May 08 2018

BRIEF-Proteon Says Has Sufficient Capital For Operations Into Q4 Of 2019

* PROTEON THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 14 2018

BRIEF-Proteon Therapeutics Completes Enrollment In Patency-2, Phase 3 Clinical Trial Of Investigational Vonapanitase

* PROTEON THERAPEUTICS COMPLETES ENROLLMENT IN PATENCY-2, PHASE 3 CLINICAL TRIAL OF INVESTIGATIONAL VONAPANITASE Source text for Eikon: Further company coverage:

Mar 05 2018

Earnings vs. Estimates